Our study aimed to identify compounds that could upregulate VMAT2 levels and activity since low VMAT2 levels are associated with BMVTD, Parkinson’s disease, and depression, and high VMAT2 levels are protective for Parkinson’s disease risk in humans and neurotoxicity in rodents [8–15, 17, 18]. This evidence concerns the gene SLC18A2 and depressive symptom measurement.